This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Santarus' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Stocks in this article: SNTS

We are pleased with the settlement agreement recently announced with GLUMETZA. Under this agreement Lupin has granted the right to begin selling a generic version of GLUMETZA on February 1, 2016. We believe we are taking the right step to lengthen the runway to continue growing GLUMETZA prescriptions and revenues, while advancing our development pipeline.

CYCLOSET net sales in the fourth quarter were $3.8 million, up approximately 81% over third quarter 2011 net sales. We expect the product will continue to growth in 2012 with increased call frequency by our larger sales organization. Turning to our development programs starting with UCERIS. Our NDA for UCERIS was accepted for review by the FDA in mid-February following its submission in December. This sets the PDUFA date for completion of the FDA review at October 16, 2012. We believe that UCERIS has the potential to be an important new therapeutic option in the treatment of ulcerative colitis, a chronic disease that afflicts an estimated 600,000 to 700,000 patients in the U.S.

We also have initiated our Phase IIIb clinical study with UCERIS to evaluate the drug as an add-on therapy to current 5-ASA drugs for the induction of our mission of our active ulcerative colitis in patients who are not adequately controlled on background 5-ASA therapy. We expect to complete patient enrollment for this study in the first half of 2013. We believe this is an important study to explore new indications to UCERIS and to provide additional data to physicians on the performance of UCERIS as add-on therapy.

We are on track this year to report a number of significant milestones with our other clinical development programs. During the first half of the year we expect to complete a Phase I clinical study with SAN-300, our anti-VLA-1 antibody program. We plan to initially evaluate SAN-300 for the treatment of rheumatoid arthritis and ultimately for the treatment of inflammatory bowel disease. By the third quarter, we also expect enrollment to be completed in a Phase 3 study with RHUCIN for the treatment acute attacks of hereditary angioedema, an orphan disease. We hold to rights to RHUCIN in the U.S., Canada and Mexico.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs